Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

bdr pharma

Tag: bdr pharma

Read all Latest developments, information and news on and about Bdr pharma

BDR pharma have carved a niche for ourselves, with our formulations portfolio for specialty medication. Their expertise with life saving medicines help us in their early identification - Latest News

BDR Pharmaceutical Gets CDSCO Panel Nod To Manufacture Market anticancer drug Tucatinib Tablets

Dr. Divya Colin9 March 2025 6:00 PM IST

New Delhi: Agreeing for Phase III clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...

BDR Pharmaceutical Gets CDSCO Panel Nod for Bioequivalence Study of Elobixibat tablet

Dr. Divya Colin1 Jan 2025 5:45 PM IST

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug...

BDR Pharmaceuticals Gets CDSCO Panel Nod for bioequvalence study of Abiraterone Acetate Oral Suspension

Dr. Divya Colin25 Dec 2024 6:15 PM IST

New Delhi: BDR Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...

Conduct Phase III clinical trial: CDSCO Panel Tells BDR Pharmaceutical on Anti-cancer Drug Abiraterone Acetate

Dr. Divya Colin20 April 2024 5:45 PM IST

New Delhi: Reviewing the justification for waiver of the Phase III clinical trial of the anti-cancer drug Abiraterone Acetate presented by BDR...

BDR Pharma Gets CDSCO Panel Nod To Study Vonoprazan Tablets

Dr. Divya Colin15 Nov 2023 6:30 PM IST

New Delhi: The drug major BDR Pharma has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...

BDR Pharma gets CDSCO panel nod to Manufacture, Market Icosapent Ethyl Capsules

Dr. Divya Colin13 Feb 2023 6:00 PM IST

New Delhi: The drug maker BDR Pharma has got approval from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organisation...

BDR Pharma launches generic APALUTAMIDE to treat Prostate cancer in India

Ruchika Sharma3 Jan 2023 12:00 PM IST

Apalutamide plus ADT (androgen-deprivation therapy) arm shows a significant decrease in the risk of disease progression and reduces risk of mortality...

CCI approves acquisition of minority stake of BDR Pharma by Multiples Private Equity Fund III, others

Ruchika Sharma19 April 2022 2:43 PM IST

The proposed combination relates to the acquisition of a minority stake by Multiples Fund III and Financial Investors in the Target.

BDR Pharma launches Enzalutamide under the brand name BDENZA

MD Bureau2 March 2022 1:16 PM IST

The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy and minimum side effects.

Dr Reddys to launch anti-COVID drug Molnupiravir under brand name Molflu at Rs 35 per capsule

Medical Dialogues Bureau5 Jan 2022 3:53 PM IST

"Molflu (Molnupiravir) is expected to be available from early next week in pharmacies throughout the country with particular focus on states with high...

Health Bulletin 31/December/2021

Roshni Dhar31 Dec 2021 5:00 PM IST

Here are Top Health stories of the dayFMGE December Result 2021 (OUT): NBE announces Foreign Medical Graduate Examination for December SessionThe...

Mankind Pharma Launches Anti-COVID-19 pill Molulife- Molnupiravir 200mg

Ruchika Sharma30 Dec 2021 1:03 PM IST

Taking a significant step towards countering COVID-19 in India, drug major Mankind Pharma has announced the launch of the oral anti- COVID...

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok